Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04551131 · ClinicalTrials.gov registry record · Phase 1
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
A Phase 1 study of Hemophagocytic Lymphohistiocytosis, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 13
- Study locations
NCT04551131: Active Phase 1 study of Hemophagocytic Lymphohistiocytosis, sponsored by St. Jude Children's Research Hospital.
NCT04551131 is a Phase 1 study of Hemophagocytic Lymphohistiocytosis that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 13 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04551131, a Phase 1 study of Hemophagocytic Lymphohistiocytosis, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as Salvage therapy for patients with relapsed/refractory HLH. Primary Objective * To determine the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with newly diagnosed HLH. Secondary Objectives * To describe the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with relapsed/refractory HLH. * To describe the overall response and outcome for patients with newly diagnosed or relapsed/refractory HLH who are treated with this response-adapted ruxolitinib-containing regimen. Exploratory Objectives * To estimate the pharmacokinetic (PK) parameters of ruxolitinib, assess covariates of ruxolitinib pharmacokinetics, and test whether the drug's effectiveness is correlated with systemic drug exposure. * To query specific immunologic biomarkers and determine whether the levels of these biomarkers correlate with disease response and outcome.
Primary Outcome
Will be reported as number and percentage of patients meeting CR/CRi criteria at the end of 8 weeks of therapy
Conditions Studied
Interventions
- DRUG Etoposide
- DRUG Dexamethasone
- DRUG Ruxolitinib
Study Locations (13)
California
- Children's Hospital of Orange County - Orange
- University of California San Francisco - San Francisco
Texas
- University of Texas Southwestern Medical Center - Dallas
- Texas Children's Hospital - Houston
Arizona
- Phoenix Children's Hospital - Phoenix
District of Columbia
- Children's National Medical Center - Washington D.C.
Maryland
- John Hopkins University - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Cohen Children's Medical Center - New Hyde Park
North Carolina
- Levine Children's Hospital - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT04551131 still lists
NCT04551131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Hemophagocytic Lymphohistiocytosis appearing as the primary indexed condition, and to 3 interventions - of which Etoposide is the first listed.
NCT04551131 lists 13 locations in 11 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT04551131 about?
NCT04551131 is a clinical study titled "Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis". This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or ...
What is the current status of trial NCT04551131?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-07-13. Estimated completion is 2026-08.
What conditions does trial NCT04551131 study?
This clinical trial studies the following conditions: Hemophagocytic Lymphohistiocytosis.
What interventions are being tested in trial NCT04551131?
The interventions under investigation include: Etoposide (DRUG), Dexamethasone (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT04551131?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04551131 being conducted?
This trial has 13 study locations across Arizona, California, District of Columbia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophagocytic Lymphohistiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04551131's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI